International Biotechnology Trust plc (IBT) - Total Assets

Latest as of August 2025: GBX284.04 Million GBX ≈ $34.56K USD

Based on the latest financial reports, International Biotechnology Trust plc (IBT) holds total assets worth GBX284.04 Million GBX (≈ $34.56K USD) as of August 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See International Biotechnology Trust plc (IBT) net assets for net asset value and shareholders' equity analysis.

International Biotechnology Trust plc - Total Assets Trend (2000–2025)

This chart illustrates how International Biotechnology Trust plc's total assets have evolved over time, based on quarterly financial data.

International Biotechnology Trust plc - Asset Composition Analysis

Current Asset Composition (August 2025)

International Biotechnology Trust plc's total assets of GBX284.04 Million consist of 0.0% current assets and 0.0% non-current assets.

Asset Category Amount (GBX) % of Total Assets
Cash & Equivalents GBX0.00 5.3%
Accounts Receivable GBX66.00K 0.0%
Inventory GBX0.00 0.0%
Property, Plant & Equipment GBX0.00 0.0%
Intangible Assets GBX0.00 0.0%
Goodwill GBX0.00 0.0%

Asset Composition Trend (2000–2025)

This chart illustrates how International Biotechnology Trust plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IBT stock market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: International Biotechnology Trust plc's current assets represent 0.0% of total assets in 2025, unchanged from 0.0% in 2000.
  • Cash Position: Cash and equivalents constituted 5.3% of total assets in 2025, up from 0.0% in 2000.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
  • Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.

International Biotechnology Trust plc Competitors by Total Assets

Key competitors of International Biotechnology Trust plc based on total assets are shown below.

Company Country Total Assets
Fortress Biotech Inc
NASDAQ:FBIO
USA $185.55 Million
Summit Therapeutics PLC
NASDAQ:SMMT
USA $261.73 Million
Tubize-Fin
BR:TUB
Belgium €1.93 Billion
Apellis Pharmaceuticals Inc
NASDAQ:APLS
USA $1.08 Billion
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
China CN¥16.55 Billion
BrightGene Bio Medical Technology C
SHG:688166
China CN¥5.38 Billion
BioArctic AB (publ)
ST:BIOA-B
Sweden Skr2.60 Billion
Chengzhi Shareholding Co Ltd
SHE:000990
China CN¥27.52 Billion

International Biotechnology Trust plc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.12 0.46 4.04
Quick Ratio 0.12 0.46 4.04
Cash Ratio 0.00 0.00 0.00
Working Capital GBX-36.46 Million GBX-18.56 Million GBX9.68 Million

International Biotechnology Trust plc - Advanced Valuation Insights

This section examines the relationship between International Biotechnology Trust plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.26
Latest Market Cap to Assets Ratio 0.01
Asset Growth Rate (YoY) -7.8%
Total Assets GBX284.04 Million
Market Capitalization $3.74 Million USD

Valuation Analysis

Below Book Valuation: The market values International Biotechnology Trust plc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: International Biotechnology Trust plc's assets decreased by 7.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for International Biotechnology Trust plc (2000–2025)

The table below shows the annual total assets of International Biotechnology Trust plc from 2000 to 2025.

Year Total Assets Change
2025-08-31 GBX284.04 Million
≈ $34.56K
-7.83%
2024-08-31 GBX308.15 Million
≈ $37.49K
+1.08%
2023-08-31 GBX304.87 Million
≈ $37.09K
-6.74%
2022-08-31 GBX326.92 Million
≈ $39.78K
-6.01%
2021-08-31 GBX347.83 Million
≈ $42.32K
+14.91%
2020-08-31 GBX302.71 Million
≈ $36.83K
+25.68%
2019-08-31 GBX240.86 Million
≈ $29.31K
-8.49%
2018-08-31 GBX263.22 Million
≈ $32.03K
-3.35%
2017-08-31 GBX272.34 Million
≈ $33.14K
+17.83%
2016-08-31 GBX231.12 Million
≈ $28.12K
-11.68%
2015-08-31 GBX261.68 Million
≈ $31.84K
+15.99%
2014-08-31 GBX225.61 Million
≈ $27.45K
+30.49%
2013-08-31 GBX172.90 Million
≈ $21.04K
+33.90%
2012-08-31 GBX129.12 Million
≈ $15.71K
+27.44%
2011-08-31 GBX101.32 Million
≈ $12.33K
+6.57%
2010-08-31 GBX95.07 Million
≈ $11.57K
-3.70%
2009-08-31 GBX98.72 Million
≈ $12.01K
-13.92%
2008-08-31 GBX114.69 Million
≈ $13.95K
+10.16%
2007-08-31 GBX104.11 Million
≈ $12.67K
+55.11%
2006-08-31 GBX67.12 Million
≈ $8.17K
+14.27%
2005-08-31 GBX58.73 Million
≈ $7.15K
+5.77%
2004-08-31 GBX55.53 Million
≈ $6.76K
+2.19%
2003-08-31 GBX54.34 Million
≈ $6.61K
+11.96%
2002-08-31 GBX48.54 Million
≈ $5.91K
-51.74%
2001-08-31 GBX100.58 Million
≈ $12.24K
-72.53%
2000-08-31 GBX366.17 Million
≈ $44.55K
--

About International Biotechnology Trust plc

LSE:IBT UK Biotechnology
Market Cap
$3.74 Million
GBX30.75 Billion GBX
Market Cap Rank
#28884 Global
#535 in UK
Share Price
GBX964.00
Change (1 day)
+0.63%
52-Week Range
GBX550.00 - GBX1000.00
All Time High
GBX1000.00
About

International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies fo… Read more